KLP Kapitalforvaltning AS Trims Position in Certara, Inc. $CERT

KLP Kapitalforvaltning AS trimmed its stake in shares of Certara, Inc. (NASDAQ:CERT) by 19.7% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 25,200 shares of the company’s stock after selling 6,200 shares during the period. KLP Kapitalforvaltning AS’s holdings in Certara were worth $295,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the stock. Public Employees Retirement System of Ohio grew its stake in Certara by 9.2% during the second quarter. Public Employees Retirement System of Ohio now owns 200,068 shares of the company’s stock valued at $2,341,000 after acquiring an additional 16,779 shares in the last quarter. AdvisorNet Financial Inc purchased a new position in Certara during the second quarter valued at $25,000. Harbor Capital Advisors Inc. grew its stake in Certara by 41.3% during the second quarter. Harbor Capital Advisors Inc. now owns 28,670 shares of the company’s stock valued at $335,000 after acquiring an additional 8,376 shares in the last quarter. Jane Street Group LLC grew its stake in Certara by 17.1% during the first quarter. Jane Street Group LLC now owns 277,054 shares of the company’s stock valued at $2,743,000 after acquiring an additional 40,463 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Certara by 13.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 299,528 shares of the company’s stock valued at $2,965,000 after acquiring an additional 35,954 shares in the last quarter. 73.96% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Certara

In related news, insider Leif E. Pedersen sold 51,224 shares of Certara stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $10.92, for a total transaction of $559,366.08. Following the completion of the transaction, the insider directly owned 73,979 shares of the company’s stock, valued at approximately $807,850.68. The trade was a 40.91% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 2.33% of the company’s stock.

Certara Price Performance

CERT stock opened at $11.97 on Monday. Certara, Inc. has a 52 week low of $8.64 and a 52 week high of $15.69. The company has a quick ratio of 2.16, a current ratio of 2.16 and a debt-to-equity ratio of 0.27. The company has a fifty day simple moving average of $11.52 and a two-hundred day simple moving average of $11.51. The firm has a market capitalization of $1.92 billion, a P/E ratio of 239.45 and a beta of 1.45.

Certara (NASDAQ:CERT) last released its earnings results on Wednesday, August 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). Certara had a return on equity of 5.11% and a net margin of 1.97%.The firm had revenue of $104.57 million during the quarter, compared to the consensus estimate of $104.14 million. During the same quarter last year, the business posted $0.07 EPS. Certara’s revenue was up 12.1% compared to the same quarter last year. Analysts anticipate that Certara, Inc. will post 0.28 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently weighed in on CERT. Barclays raised their target price on shares of Certara from $14.00 to $16.00 and gave the company an “overweight” rating in a research note on Thursday, October 2nd. Morgan Stanley assumed coverage on shares of Certara in a research note on Thursday, July 3rd. They set an “equal weight” rating and a $16.00 target price for the company. KeyCorp increased their price objective on shares of Certara from $15.00 to $16.00 and gave the company an “overweight” rating in a research report on Wednesday, October 8th. Weiss Ratings reiterated a “sell (d)” rating on shares of Certara in a research report on Wednesday, October 8th. Finally, Craig Hallum assumed coverage on shares of Certara in a research report on Monday, September 29th. They set a “buy” rating and a $16.00 price objective for the company. Six investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $15.63.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.